| Unsubscribe |
It was the biggest stock market flotation in history.
It created the world’s first ever trillionaire.
But it may have caused millions of Americans to miss the single most important change to their money in more than 50 years.
Because, while everyone’s distracted by the SpaceX frenzy, Washington is quietly rewriting the rules of your financial life.
It wasn't voted on. It wasn't debated in the Senate. And most Americans have no idea it's even taking place but…
President Trump is replacing the U.S. dollar.
Not with crypto. Not with a digital currency. Something far bigger than that – and it's already been signed and sealed in the back rooms of D.C., ready to be issued by the U.S. Treasury.
Bypassing every legal and political channel under the guise of "national security," Trump has enacted this total money reset using a landmark executive order (14241).
Whether you’re a Democrat or Republican, whether you support this new money or not, it doesn't matter.
Soon, every U.S. citizen will be forced to use Trump's New Dollar to fill their gas tank, buy groceries, and pay medical bills.
Which is why I've produced a critical new documentary laying out exactly what Trump's New Dollar means for your savings, your investments, and your family's financial future.
Detailing three important steps you can take today to prepare – including the name of a core band of assets connected to Trump’s initiative that could surge as a result.
As you’ll see in my briefing, the last time America reset its money like this – under Richard Nixon’s presidency in the 1970s – it created one of the greatest wealth divides in the history of our nation.
On one side, it minted an average of 1,300 new millionaires a day for over half a century. And on the other… the folks left behind, drowning in debt, with no idea how to use America’s new money to create wealth.
As Trump rolls out his new dollar, the question is:
Good investing,
Porter Stansberry
PS. If you’re wondering what Trump’s new money will look like, when it will be issued, what it means for your investments – all of those questions are answered in my briefing.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Reported by Jeffrey Neal Johnson. Originally Published: 7/13/2026.
Key Points
- Wainua failed its CARDIO-TTRansform Phase 3 trial by showing no additive benefit for patients already taking stabilizer drugs like Vyndamax.
- Ionis Pharmaceuticals shares fell more than 9% on concentrated pipeline risk, while AstraZeneca's much larger, diversified business barely felt the impact.
- Rivals BridgeBio, Pfizer, and Alnylam Pharmaceuticals gained ground as the trial failure preserved their competitive positions in the amyloidosis treatment market.
- Special Report: SpaceX is offering you shares. Don't take them.
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely spreads evenly across the board. The fallout often reveals hard truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments. The July 9 announcement from AstraZeneca (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) regarding the CARDIO-TTRansform Phase 3 trial offers a real-time masterclass in these market dynamics.
The investigational use of Wainua, also known as eplontersen, failed to achieve statistical significance on its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events at 140 weeks. The treatment targets transthyretin-mediated amyloid cardiomyopathy, a fatal disease that causes misfolded proteins to build up in the heart muscle.
3 AI stocks to buy before August 2026 (Ad)
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005.
Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
Click here to get all three AI stock names from Alexander GreenThe clinical failure removes an anticipated competitor from a highly lucrative market and triggers an immediate capital rotation across the broader biotech sector.
Unmasking the Trial: Stabilizers Block the Path
To understand why the market repriced these assets so aggressively, investors need to look beyond the headline failure and examine the subgroup data. The treatment landscape relies heavily on stabilizer medications like Vyndamax, manufactured by Pfizer (NYSE: PFE). In the CARDIO-TTRansform trial, patients already taking these baseline stabilizers accounted for 57% of the study population at the start of the program, and that proportion rose to roughly 80% by the end of the study.
Wainua failed to demonstrate an additive treatment effect in this stabilizer subgroup. The drug did not improve outcomes for patients who were already receiving standard-of-care treatment.
In the monotherapy subgroup, which includes patients not taking any stabilizers, Wainua demonstrated a hazard ratio of 0.71, translating to a 29% risk reduction. While that figure aligns closely with competitor benchmarks, it offers little commercial utility. A pharmaceutical product cannot capture meaningful market share if it only works for the rapidly shrinking fraction of patients who are completely naive to standard-of-care treatments.
This data exposes a fundamental difference between antisense oligonucleotides like Wainua and RNA interference therapies developed by competitors. Alnylam Pharmaceuticals (NASDAQ: ALNY) previously validated its competing RNA interference therapy, Amvuttra, across both the monotherapy subgroup and the subgroup combined with a stabilizer in its HELIOS-B trial. By failing to show that essential additive benefit, Wainua is effectively locked out of the most lucrative and pre-treated segment of the total addressable market.
Asymmetric Damage: Single Asset Squeeze
The financial damage stemming from this clinical miss was distributed unevenly, highlighting the stark contrast between concentrated pipeline risk and structural business diversification.
Ionis Pharmaceuticals absorbed the brunt of the impact. Shares fell by more than 9% in a single day, pushing the stock down more than 26% since the start of the year and compressing its total market capitalization to $9.63 billion.
Ionis Pharmaceuticals faces acute vulnerability because it relies on expanding the addressable market for Wainua. The current regulatory approval for ATTR-polyneuropathy covers fewer than 50,000 patients globally.
The cardiomyopathy indication would have opened a total addressable market of 300,000 to 500,000 patients.
Without that expansion, Ionis Pharmaceuticals faces a difficult fundamental reality. The developer currently generates negative earnings, with an earnings-per-share loss of 56 cents. First-quarter 2026 revenue surged to $246 million, an 87% increase year over year, but rapid commercial infrastructure expansion kept profit margins compressed, resulting in a net loss of $93 million.
While the company's trailing return on equity remained deeply negative at -58.65%, its balance sheet risk eased substantially after Ionis eliminated $633 million in convertible debt using restricted escrow cash on April 1, 2026.
AstraZeneca tells a very different fundamental story. AstraZeneca's stock price fell briefly intraday before institutional buyers stepped in to support it. A $266.54 billion pharmaceutical sector giant does not live or die by a single indication expansion.
AstraZeneca generates $60.44 billion in annual sales, supported by blockbuster oncology franchises such as Tagrisso and Imfinzi. The company operates with a healthy 17.19% net margin, a robust 30.86% return on equity, and a conservative debt-to-equity ratio of 0.52.
Pre-trial models projected that Wainua could reach peak sales of up to $6.5 billion with ATTR-CM approval.
Analysts have since revised those estimates down to approximately $4 billion. Erasing a $2.5 billion premium certainly adjusts near-term valuation models, but it barely registers against AstraZeneca's stated $80 billion top-line revenue target for 2030. The institutional market accurately viewed the drop as a temporary mispricing rather than a structural downgrade.
The Vultures Circle: Rivals Catch the Tailwinds
Markets dislike a vacuum. When Wainua was removed as an imminent competitive threat, capital immediately rotated into rival drugmakers positioned to capture that unaddressed market share. The trial failure preserves the current duopoly and triopoly pricing power within the disease space.
BridgeBio (NASDAQ: BBIO) emerged as the most direct beneficiary, with shares up 16% to touch new 52-week highs following the initial announcement. BridgeBio is actively launching its newly approved therapy, Attruby.
Without Wainua entering the market to compress margins and force aggressive discounting, BridgeBio enjoys a heavily cleared commercial runway. BridgeBio recently secured a $1 billion Series A convertible preferred equity raise led by Sixth Street and KKR. This infusion provides a substantial capital buffer to execute an aggressive, unopposed commercial launch, funding sales force deployment without immediate dilution concerns.
Pfizer and Alnylam Pharmaceuticals also experienced immediate bid support. Pfizer maintains its multi-billion-dollar stronghold with Vyndamax, resting easy knowing that physicians will not have to weigh the transition of stable patients to a competing therapy. Alnylam Pharmaceuticals sustains its clinical momentum, as its RNA interference mechanism remains the only proven combination therapy that effectively stacks on top of existing stabilizers.
Discharging the Risk: Portfolio Lessons Learned
The failure of the CARDIO-TTRansform trial fundamentally rewrites the competitive map for amyloidosis treatments. It draws a hard line between therapies that can improve the standard of care and those that merely match it in isolation.
For the companies involved, the data reinforces the protective power of a diversified revenue base. AstraZeneca can easily absorb the setback through its oncology and metabolic divisions, while Ionis Pharmaceuticals faces prolonged fundamental pressure as it navigates elevated debt levels and stalled growth drivers. Investors evaluating biotech allocations might consider prioritizing developers with validated combination therapies or deeply diversified pipelines to help mitigate these specific clinical risks.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
Reported by Jeffrey Neal Johnson. Originally Published: 7/10/2026.
Key Points
- AeroVironment’s fiscal 2030 targets triggered analyst concern about execution risk, even as management pointed to strong long-term demand.
- AeroVironment’s fiscal fourth-quarter results showed record revenue, strong adjusted EBITDA and a larger funded backlog.
- The company’s counter-drone contract wins support the bullish case, but investors still need to weigh valuation, integration risk and the timing of government spending.
- Special Report: SpaceX is offering you shares. Don't take them.
Wall Street analysts reacted sharply recently when AeroVironment's (NASDAQ: AVAV) management unveiled an aggressive revenue target of $3.5 billion to $4 billion for fiscal 2030. The immediate response was a wave of synchronized downgrades, with analysts citing execution risk and flat macroeconomic defense budgets.
The resulting sell-off contributed to a 38% year-to-date pullback, pushing AeroVironment's stock price close to its 52-week low. When institutional investors focus too heavily on near-term organic guidance, they can miss the broader structural shift unfolding in plain sight.
3 AI stocks to buy before August 2026 (Ad)
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005.
Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
Click here to get all three AI stock names from Alexander GreenThe prevailing narrative suggests AeroVironment needs a dramatic, back-weighted acceleration to hit its 2030 goals. Analysts looked at the projected 10% organic growth for fiscal 2027 and concluded that the math for the end of the decade was too difficult to achieve. That skepticism triggered a sharp repricing, creating a steep discount for investors willing to look past headline volatility.
Clearing the Air on the 2030 Roadmap
A closer examination of recent financial metrics, strategic acquisitions, and immediate contract monetization reveals a very different reality for AeroVironment. The underlying growth trajectory is not only visible, but also effectively de-risked by recent operational execution. The data points to a sharp disconnect between price action and business fundamentals.
Modern kinetic conflicts have fundamentally altered global military doctrine. The Pentagon is actively redirecting procurement budgets away from slow, expensive legacy platforms like fighter jets and toward attritable, unmanned systems and Counter-UAS technology. AeroVironment is positioned as a premier pure-play asset in this space, making the macroeconomic argument about flat defense budgets largely irrelevant to its specific product suite.
Profitability Takes Flight in Fiscal Q4
Understanding the valuation disconnect requires looking at the raw data from the fiscal fourth quarter of 2026. AeroVironment delivered a blowout earnings report, generating a record $642 million in quarterly revenue. That represents a 31% year-over-year organic growth rate. Most importantly, AeroVironment reported $140 million in Adjusted EBITDA, translating to a 22% margin.
This margin metric directly undercuts the primary bearish argument. Major firms downgraded the stock because they doubted management's ability to reach its stated 2030 target of 18% to 20% Adjusted EBITDA margins. The earnings data show AeroVironment is already operating comfortably above that threshold.
In the defense technology sector, operating leverage is a critical driver of shareholder value. As revenue scales through the mass production of unmanned systems, fixed engineering and administrative costs are spread across a larger base, driving more cash flow directly to the bottom line.
Analysts are effectively pricing in severe margin compression to justify their lowered price targets, yet the most recent filings refute that assumption. Management is not chasing a futuristic profitability goal; it is already executing above it today.
Securing the Shield With a $500M Army Contract
AeroVironment positioned itself well for the Pentagon's strategic pivot through the integration of BlueHalo. This acquisition nearly doubled AeroVironment's operational footprint and established a dominant position in the highly lucrative Counter-UAS market.
Proof of this strategic dominance arrived quickly via a $500 million sole-source contract for the U.S. Army's JIATF-401 Domestic Shield Program. A sole-source award is a strong vote of confidence. It means the Department of Defense bypassed the standard competitive bidding process entirely, viewing AeroVironment's technology as a unique, irreplaceable necessity.
Skeptics often argue that large government contracts take years to monetize, creating a lag between headline numbers and recognized revenue. However, AeroVironment immediately booked an $80.5 million task order against this vehicle for its Titan system. This swift conversion from theoretical contract value to tangible cash flow highlights a highly efficient procurement cycle.
This contract adds to AeroVironment's multi-year visibility. The defense contractor currently holds a $1.2 billion funded backlog alongside a $1.5 billion unfunded backlog. Funded backlog represents dollars already appropriated by Congress and assigned to specific deliverables, essentially guaranteeing future revenue. An unfunded backlog indicates indefinite-delivery vehicles in which the maximum value is set, but orders are placed incrementally over time. Together, these $2.7 billion pipelines provide a thick layer of insulation against broader macroeconomic headwinds.
Catching Bears in the Crosshairs
The recent 38% price drop is tied heavily to market mechanics rather than fundamental deterioration. Short interest currently hovers around 12.6% of the float, translating to roughly 4.8 million shares sold short. The days-to-cover ratio is 4.6, indicating it would take nearly five days of average trading volume for short sellers to fully exit their positions.
This data frames the post-Investor Day sell-off as an aggressive short-selling distortion. Short sellers bet heavily on the execution-risk narrative. When a business navigating negative trailing net margins trades at a forward price-to-earnings multiple of 44, it naturally attracts bearish speculators looking to capitalize on perceived overvaluation.
The bears are anchoring their thesis to trailing profitability metrics rather than forward cash flow and aggressive backlog conversion. As those newly minted task orders convert to recognized revenue at 22% margins, the fundamental floor beneath the stock rises.
A manufactured dip driven by weak hands and overzealous short sellers creates a highly volatile, asymmetric environment. If upcoming earnings reports continue to validate the $4 billion revenue roadmap, short sellers will be forced to buy back shares at higher prices to cover their positions, potentially triggering an upside re-rating for AeroVironment.
Preparing for a Permanent Shift in Procurement
The market is currently mispricing a premier growth asset in the defense technology space. While the 2030 targets sound highly ambitious on paper, the operational groundwork is firmly established and actively generating cash. The combination of record EBITDA margins, sole-source contract dominance, and a multi-billion-dollar backlog paints a picture of a business quietly taking market share while Wall Street looks the other way.
Investors seeking exposure to the permanent shift in global military doctrine might view this volatility as a rare structural opportunity. The Pentagon's transition toward swarm drones and loitering munitions is not a temporary trend, but a permanent evolution of defense spending.
Cautious market participants may prefer to wait for the next quarterly earnings report to confirm ongoing backlog monetization before taking a position. Those with a higher risk tolerance might consider the current valuation disconnect a compelling moment to evaluate AeroVironment before the broader market digests the reality of its long-term trajectory.
to bring you the latest market-moving news.
This email is a paid sponsorship provided by Porter & Company, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights protected.
345 N Reid Pl. #620, Sioux Falls, S.D. 57103. United States..
No comments:
Post a Comment